Author Archives: admin


Gujarat Issues Health Advisory On Fungal Infection With "50% Mortality Rate" – NDTV

Gujarat health advisory lists SOPs against mucormycosis. Wearing masks is one of them.

The Gujarat health department has issued an advisory to doctors and health officials after some COVID-19 patients were recently found infected with mucormycosis, saying it a serious but rare fungal infection and has an overall "mortality rate of 50 per cent".

As per the advisory issued on Monday, mucormycosis infects people with weak immune system and having other existing illnesses.

The Gujarat health department said the advisory is being issued after some coronavirus patients in Ahmedabad and Rajkot were found infected with mucormycosis, which is "serious but rare infection caused by a group of molds called mucormycetes".

"It most commonly affects the sinuses or lungs after inhaling fungal spores from the air, or the skin after the fungus enters through a cut, burn or other type of skin injury. However, it can occur in any part of the body," said the advisory.

It said though the "overall mortality rate is around 50 per cent", early identification and treatment can help.

The advisory said people having diabetes or cancer, or those who underwent organ transplant, stem cell transplant or people having too much iron in the body are at a greater risk of contracting this infection.

The health department made it clear that mucormycosis "cannot spread between people or between people and animals".

"People get mucormycosis through contact with fungal spores in the environment," it said.

Enlisting some preventive measures, like wearing N95 masks, the advisory said these are recommendations and they "have not been proven to prevent mucormycosis".

Apart from wearing the N95 mask, people should avoid direct contact with lot of dust, wear shoes, long pants and gloves while handling soil or moss, and clean skin injuries well with soap and water, said the advisory.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Read this article:
Gujarat Issues Health Advisory On Fungal Infection With "50% Mortality Rate" - NDTV

A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines – STAT

In an ideal world, a pandemic vaccine could be delivered in a single shot, so supplies could be stretched to cover a lot of people. It would trigger no side effect more significant than a sore arm. And it would be easy to ship and store.

Unfortunately, this is not an ideal world not yet, anyway.

For now, the good news is that the United States has two Covid-19 vaccines that have been shown to be highly effective.

advertisement

What follows is a head-to-head comparison of the ones developed by Pfizer and its partner, BioNTech, and by Moderna. Note that the chances of most individuals being able to pick one or the other are slim to none, especially in the initial rollout. The vaccine available is the one youll get.

The Pfizer emergency use authorization is for people aged 16 and older. Modernas is for people 18 and older, though the company has recently begun testing its vaccine in 12- to 17-year-olds.

advertisement

Both vaccines have shown astonishing and essentially equivalent degrees of efficacy, at least in the early stages after vaccination. How they stack up over the long term remains to be seen.

The Pfizer vaccine showed efficacy of 95% at preventing symptomatic Covid infection, measured starting from seven days after the second dose was administered. The vaccine appeared to be more or less equally protective across age groups and racial and ethnic groups.

The Moderna vaccine was 94.1% effective at preventing symptomatic Covid-19, measured starting from 14 days after the second dose. The vaccines efficacy appeared to be slightly lower in people 65 and older, but during a presentation to the Food and Drug Administrations advisory committee the company explained that the numbers could have been influenced by the fact there were few cases in that age group in the trial. The vaccine appeared to be equally effective across different ethnic and racial groups.

Both vaccines seemed to reduce the risk of severe Covid disease. Its not yet known if either prevents asymptomatic infection with the SARS-CoV-2 virus. Nor is it known if vaccinated people can transmit the virus if they do become infected but dont show symptoms.

Both the Moderna and the Pfizer/BioNTech vaccines require two shots: a priming dose, followed by a booster shot. The interval between Moderna doses is 28 days; for the Pfizer vaccine, its 21 days.

Each dose of Pfizers contains 30 micrograms of vaccine. Moderna went with a much larger dose of vaccine, 100 micrograms. It means it is using a little more than three times as much vaccine per person as Pfizer is. And yet, they arent getting better results.

In the vernacular of vaccinology, vaccines that trigger a range of transient side effects in a lot of recipients are known as reactogenic.

Both these vaccines in fact, most if not all the Covid-19 vaccines that have reported data so far fall into the reactogenic category. The Advisory Committee on Immunization Practices, an expert panel that helps the Centers for Disease Control and Prevention set vaccination policies, has advised hospitals they may want to stagger vaccinations among staff for instance, dont vaccinate all the emergency room staff at the same time in case some feel too unwell to work the day after being vaccinated.

The most common side effects are injection site pain, fatigue, headache, muscle pain, and joint pain. Some people in the clinical trials have reported fever. Side effects are more common after the second dose; younger adults, who have more robust immune systems, reported more side effects than older adults.

To be clear: These side effects are a sign of an immune system kicking into gear. They do not signal that the vaccine is unsafe. To date there are no serious, long-term side effects associated with receipt of these vaccines, which will be closely monitored as their use expands.

There have been a handful of reports of people having allergic reactions to the Pfizer vaccine since its rollout began. Those reactions anaphylaxis or a less severe allergic reaction were not seen in the clinical trials. It remains to be seen if similar events will be seen with the Moderna vaccine.

Neither of the vaccines has been tested in these two groups.

Moderna has completed animal studies the FDA demanded of manufacturers; these studies look for evidence that the vaccine might harm the pregnancy or the developing fetus. The company said it saw no such signals.

Pfizer has only interim data from its animal studies, but said it saw no concerning signs either.

The authorizations for both vaccines state there are not enough data to gauge whether they are safe for pregnant or lactating people. FDAs Peter Marks, director of the Center for Biologics Evaluation and Research, said Friday that those who are pregnant should choose whether to be vaccinated after discussing the risks and benefits with their physicians.

Both of these vaccines require an elaborate cold chain, the term used to describe the conditions under which vaccines must be stored during distribution and when they are in the doctors offices, pharmacies, or public health clinics where theyll be administered.

But the Moderna vaccine will be far easier to use than Pfizers. For starters, Modernas must be shipped at -4 Fahrenheit; Pfizers must be shipped and stored at -94 Fahrenheit. The former is the temperature of a regular refrigerator freezer; the latter requires special ultra-cold freezers that need to be topped up with dry ice every five days. Doctors offices do not have ultracold freezers; neighborhood pharmacies dont either.

After thawing, a vial of the Pfizer vaccine must be used within five days; Modernas is stable at fridge temperature for 30 days and at room temperature for 12 hours.

The ultracold storage requirement is not the only challenging aspect of the Pfizer vaccine. The minimum amount of vaccine a location can order is 975 doses. A large teaching hospital might need several of those. But there are plenty of places across the country that dont need 975 doses to vaccinate the people currently eligible for vaccination health workers and nursing home residents. This is the vaccine that needs to be kept at -94 F. The minimum order size will limit the locations in which this vaccine can be used.

The Moderna vaccines minimum order is 100 doses, a much more manageable number.

The Pfizer vaccine is shipped in five-dose vials; Modernas vaccine is shipped in 10-dose vials.

Figuring out how long the protection provided by either of these vaccines will last will take time. Its going to involve periodic blood draws from some volunteers to see what their antibody levels look like, though a decline in antibody levels doesnt necessarily equate to loss of protection.

But a large part of this work will involve watching for reports that people who were immunized are starting to contract Covid in larger numbers, a development that would probably lead to recommendations to give people booster shots at some yet-to-be-determined interval.

Senior Writer, Infectious Disease

Helen covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development.

Trending

Let the ultra-rich and influential skip the line for

Let the ultra-rich and influential skip the line for Covid-19 vaccines? Hear me out

The story of mRNA: How a once-dismissed idea became

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine

Watch: What to expect when youre injected: Vaccine side

Watch: What to expect when youre injected: Vaccine side effects explained

Recommended

Let the ultra-rich and influential skip the line for

Let the ultra-rich and influential skip the line for Covid-19 vaccines? Hear me out

Beware the danger of vaccine euphoria

Beware the danger of vaccine euphoria

3 lessons from Stanfords Covid-19 vaccine algorithm debacle

3 lessons from Stanfords Covid-19 vaccine algorithm debacle

See the article here:
A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines - STAT

Comprehensive Report on Animal Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | ANIMAL CELL THERAPIES,…

Animal Stem Cell Therapy Marketresearch report is the new statistical data source added byA2Z Market Research.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Animal Stem Cell Therapy Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=286567

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

ANIMAL CELL THERAPIES, Celavet, Animacel, VETSTEM BIOPHARMA, Cell Therapy Sciences, Magellan Stem Cells, Cells Power Japan, Animal Care Stem, Aratana Therapeutics, VetCell Therapeutics, MediVet Biologic, U.S. Stem Cell, J-ARM

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Stem Cell Therapy markets trajectory between forecast periods.

Global Animal Stem Cell Therapy Market Segmentation:

Market Segmentation: By Type

Dogs Horses Others

Market Segmentation: By Application

Veterinary Hospitals Research Organizations

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=286567

Regions Covered in the Global Animal Stem Cell Therapy Market Report 2021: The Middle East and Africa(GCC Countries and Egypt) North America(the United States, Mexico, and Canada) South America(Brazil etc.) Europe(Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Animal Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Animal Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Animal Stem Cell Therapy market.

Table of Contents

Global Animal Stem Cell Therapy Market Research Report 2021 2027

Chapter 1 Animal Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=286567

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the rest here:
Comprehensive Report on Animal Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | ANIMAL CELL THERAPIES,...

Canine Stem Cell Therapy Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026 – Factory Gate

The latest report by AllTheResearch specifies all aspects of the globalCanine Stem Cell Therapy industry. A comparative study of the global and regional market has been given. In addition, the document delivers current as well as upcoming technical and financial details with global Canine Stem Cell Therapy market risk, growing demand, and raw materials. The research document studies prominent manufacturers of the market and discusses aspects such as organization profiles, production, cost, sales, product specification, potential, and other essentials.

The historical and current market trends are taken into consideration while predicting the prospects of the Canine Stem Cell Therapy Market. Further, the study introspects the major trends that are likely to impact the growth of the Canine Stem Cell Therapy Market during the forecast period 20162026.

Request for a sample copy of the report to get extensive insights into Canine Stem Cell Therapy market @ https://www.alltheresearch.com/sample-request/206

Top Key Players of Canine Stem Cell Therapy Market

The investors, stakeholders, emerging and established players can leverage the data included in the report to develop impactful growth strategies and improve their position in the current Canine Stem Cell Therapy Market landscape. The report provides a thorough assessment of the micro and macro-economic factors that are expected to impact the growth of the Canine Stem Cell Therapy Market.

Market Broadly Classified Canine Stem Cell Therapy Market Segmentation

By Type

By Application

Any queries, have questions or need customization on above report? Speak with industry expert @ https://www.alltheresearch.com/speak-to-analyst/206

Regional Growth Analysis:

The regional analysis assists market players to explore unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets. Additionally, analysis of the market concentration rate, as well as the concentration ratio over the estimated period, is presented. All major regions and countries have been covered in the global Digital Timer market report.

Based on geography, the global market has been segmented into:

How Does This Market Research Report Help?

Purchase the full report with detailed information of Covid19 impact analysis & post-pandemic revenue opportunities @ https://www.alltheresearch.com/buy-now/206

About Us: AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT: Contact Name: Rohan S. Email: [emailprotected] Phone: +1 (407) 768-2028

See the rest here:
Canine Stem Cell Therapy Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026 - Factory Gate

Spectrum Antimicrobials, Inc. Announces the Launch of its Animal Health Division

PETALUMA, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Spectrum Antimicrobials, Inc., announces the launch of Vetricept Skin and Wound Care Cleanser, the first product launch in the Company’s new Animal Health Division. Vetricept uses a new patent pending formula developed for advanced wound care. Vetricept contains a modified chemistry containing hypochlorous acid (HOCl), which is naturally produced by mammalian immune systems to control and fight infection.

See the rest here:
Spectrum Antimicrobials, Inc. Announces the Launch of its Animal Health Division

U.S. Partner Secures Licensing Rights to 2,400 Retail Stores

CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- On December 21, 2020 Biosenta’s U.S. licensing partner Kleen Bee Labs, LLC has secured licensing rights in Ralphs and Food 4 Less retailers, which are divisions of Kroger Corp. Kroger Corp is one of the largest retailers in the US with approx. 2,400 stores. Kleen Bee Labs long term goal is to distribute in over 10,000 stores across the United States.

More here:
U.S. Partner Secures Licensing Rights to 2,400 Retail Stores

Valneva Shareholders Approve EGM Resolutions to Support Potential US IPO Plan

Saint-Herblain (France), December 22, 2020 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting (EGM) held on December 22, 2020.  Due to the COVID-19 pandemic, this EGM was held as a closed meeting without the physical presence of shareholders.  Full voting results will be available on the Company’s website within fifteen days.

Here is the original post:
Valneva Shareholders Approve EGM Resolutions to Support Potential US IPO Plan

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat Still’s disease has been accepted by the United States Food and Drug Administration (FDA) and is now open. CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb). The first study will be a global multicenter Phase 1b clinical trial in adult onset Still’s disease and is planned to start in the first quarter of 2021. Initial data is expected in the second quarter of 2021.

Read more:
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease

Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price…

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting approval of the Company’s request to transfer its listing to the Nasdaq Capital Market from the Nasdaq Global Select Market. The Company’s securities will begin trading on the Nasdaq Capital Market effective at the start of trading on December 24, 2020. The Company’s shares will continue to trade on Nasdaq under the symbol “ADXS.”

Read the original post:
Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price...